Richard Sutejo
Fakultas Biomedis (Biomedicine), Indonesia’s International Institute For Life Science (i3L), Jakarta, Indonesia

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

Epidermodysplasia verruciformis - symptoms, causes, diagnosis and treatment Sutejo, Richard
Cermin Dunia Kedokteran Vol 41, No 5 (2014): Muskuloskeletal
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1054.315 KB) | DOI: 10.55175/cdk.v41i5.1137

Abstract

Epidermodysplasia verruciformis is a rare dermal disease made popular by “Tree Man” in November 2007. The disease is caused by rare autosomal recessive hereditary genetic disorder located on chromosome 17 which causes mutation on EVER1 and EVER2 genes. An abnormality in Major Histocompatibility Complex Class II (MHC II) allele DC-DQ has also been documented in patients in America, Europe and Africa continents. These mutations increased vulnerabilities to Human Papillomavirus (HPV) causing uncontrolled wart growth, prominent in arms, neck, and legs. The common initial detection of Epidermodysplasia verruciformis is through biopsy on predicted premalignant and malignant skin lesions. Further confirmatory analysis can be performed by in-situ hybridization and polymerase chain reaction. The medical treatment is generally not definitive; typically with topical drugs such ad imiquimod, 5-fluorouracil, vitamin A derivative 13-cis retinoic acid, interferon alpha or cholecalciferol analogues (Vitamin D). For severe cases, surgical procedures to remove excessive warts are necessary.Epidermodysplasia verruciformis merupakan penyakit kulit langka yang dikenal sejak kemunculan manusia pohon pada November 2007. Penyakit ini disebabkan oleh kelainan genetik keturunan autosomal resesif di kromosom 17 yang menyebabkan mutasi gen EVER1 dan EVER2. Selain itu, juga ditemukan kelainan pada Major Histocompatibility Complex kelas II(MHC II) pada alel DC-DQ pada pasien di benua Amerika, Eropa dan Afrika. Semua mutasi abnormal ini menyebabkan kerentanan terhadap infeksi Human Papillomavirus (HPV) yang menyebabkan pertumbuhan kutil tak terkontrol terutama di daerah tangan, leher dan kaki. Tindakan awal deteksi Epidermodysplasia verruciformis adalah biopsi daerah lesi yang diprediksi premaligna dan maligna, dapat dikonfirmasi dengan proses in-situ hybridization dan polymerase chain reaction. Terapi tidak definitif, dermatologis biasanya menggunakan obat topikal seperti imiquimod and 5-fluorourasil, senyawa turunan vitamin A asam 13-cis retinoik, interferon alfa atau analog kolekalsiferol (Vitamin D). Untuk kasus parah, diperlukan operasi untuk membuang kutil yang berlebih. 
The antiviral activity of Laportea decumana methanolic extract against NDV virus Tee, Albert; Pho, Duc Khiem; Beatrix, Musung Anastasia; Dorothy, Wijaya; Sutejo, Richard
Pharmaciana Vol. 14 No. 2 (2024): Pharmaciana
Publisher : Universitas Ahmad Dahlan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.12928/pharmaciana.v14i2.28083

Abstract

The avian species virus that causes Newcastle disease is an extremely contagious illness. Avian paramyxovirus 1, or Newcastle disease virus (NDV), is a virus that brings harm to poultry's central nervous system and digestive tract. The NDV outbreak was initially documented in 1928 in Java, Indonesia. Newcastle disease does not currently require therapy. One popular and useful strategy for preventing and treating viral infections, such as Newcastle disease, is vaccination. With a variety of native medicinal plants and an abundance of biodiversity, Indonesia presents a promising area for biotechnology and pharmaceutical research. Laportea decumana, is a native plant in the Eastern part of Indonesia that contains alkaloids, glycosides, steroids, flavonoids, tannin, and saponin. Its cytotoxic, analgesic, antioxidant, and antibacterial properties have all been demonstrated. The antiviral properties of L. decumana have not been extensively researched. Thus, the purpose of this study is to examine L. decumana's antiviral activity, particularly against NDV, using a variety of techniques, including the plaque assay, cytotoxicity test, and gene expression experiment. L. decumana extracts at 100 mikrogram per mL or less is a safe concentration to consider, as it still has 65 persen and above cell viability based on the results of the cytotoxic assay.
The antiviral activity of Laportea decumana methanolic extract against NDV virus Tee, Albert; Pho, Duc Khiem; Beatrix, Musung Anastasia; Dorothy, Wijaya; Sutejo, Richard
Pharmaciana Vol. 14 No. 2 (2024): Pharmaciana
Publisher : Universitas Ahmad Dahlan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.12928/pharmaciana.v14i2.28083

Abstract

The avian species virus that causes Newcastle disease is an extremely contagious illness. Avian paramyxovirus 1, or Newcastle disease virus (NDV), is a virus that brings harm to poultry's central nervous system and digestive tract. The NDV outbreak was initially documented in 1928 in Java, Indonesia. Newcastle disease does not currently require therapy. One popular and useful strategy for preventing and treating viral infections, such as Newcastle disease, is vaccination. With a variety of native medicinal plants and an abundance of biodiversity, Indonesia presents a promising area for biotechnology and pharmaceutical research. Laportea decumana, is a native plant in the Eastern part of Indonesia that contains alkaloids, glycosides, steroids, flavonoids, tannin, and saponin. Its cytotoxic, analgesic, antioxidant, and antibacterial properties have all been demonstrated. The antiviral properties of L. decumana have not been extensively researched. Thus, the purpose of this study is to examine L. decumana's antiviral activity, particularly against NDV, using a variety of techniques, including the plaque assay, cytotoxicity test, and gene expression experiment. L. decumana extracts at 100 mikrogram per mL or less is a safe concentration to consider, as it still has 65 persen and above cell viability based on the results of the cytotoxic assay.
Assessing The Factors That Influence The Acceptance And Adoption Of The Use Of New Performance Technology Systems In Indonesia Drugstores By Pharmacists Using The Utaut-2 Model Insani, Dini Rohmatul; Sutejo, Richard
Journal of Strategic Innovation and Business Management 2025: JSIBM Vol 01 No.01
Publisher : Fakultas Bisnis - Institut Bio Scientia International Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.54250/bh6zjk68

Abstract

The rapid acceleration of digital transformation, especially during the COVID-19 pandemic, has drastically reshaped consumer behavior and necessitated adaptation within the healthcare sector, including pharmacy retail. Independent drugstores in Indonesia face mounting pressure to digitalize their operations to meet evolving customer demands, particularly through the adoption of integrated pharmacy operational systems (e-iPOS). This research examines the factors influencing pharmacists’ acceptance and use of such digital systems using the Unified Theory of Acceptance and Use of Technology 2 (UTAUT-2) model. A structured questionnaire was distributed to pharmacists across Indonesia, with 202 valid responses analyzed through structural equation modeling using SmartPLS. The study reveals that social influence, price value, and habit significantly affect pharmacists’ behavioral intention to adopt e-iPOS, with habit also directly influencing actual usage behavior. Surprisingly, traditional constructs like performance expectancy and effort expectancy were not significant predictors. These findings underscore the importance of peer influence, perceived value, and behavioral habituation in driving technology adoption in the pharmaceutical sector. The results provide actionable insights for developers of digital pharmacy platforms and health policymakers aiming to support digital transformation in independent pharmacies, particularly through tailored training, pricing strategies, and advocacy campaigns involving key opinion leaders in the pharmacy community.